Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 11, 2019. The document serves as a transaction notification regarding insider trading activities by a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions.
Material Changes and Transaction Details
The filing details two related transactions executed on February 8, 2019, by Mr. R G Connor, President of Global Vaccines:
- Option Exercise: Exercise of options over 6,910 Ordinary Shares granted on February 22, 2010, at a price of £12.0350 per share.
- Share Sale: Immediate sale of the 6,910 Ordinary Shares on the London Stock Exchange (XLON) at a price of £15.5781 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a PDMR transaction.
Investor Verification Checklist
- Verify the total number of shares held by Mr. R G Connor post-transaction.
- Confirm the timing of the option grant (February 22, 2010) relative to the exercise date.
- Review the share price movement between the exercise price (£12.0350) and the sale price (£15.5781).